Silymarin capsule in COVID-19

Evaluation of the effectiveness of Silymarin (Silybum marianum) capsule on the clinical symptoms of outpatients with COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180103038199N10

Enrollment

140

Registered

2022-01-24

Start date

2022-02-20

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19

Interventions

Intervention 1: Control group: Receive common therapies + herbal medicine placebo (capsule containing microcellulose starch (Avisel), which is similar to the capsule of the intervention groups and is

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Outpatients with COVID-19 Confirmed with RT-PCR SPO2 more than 90% Age between 18 to 60 years old

Exclusion criteria

Exclusion criteria: Pregnant women Breastfeeding women

Design outcomes

Primary

Measure	Time frame
Time to recover from illness based on questionnaire. Timepoint: Before intervention and 3, 7 and 10 days after beginning the intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Reza Askari

Mashhad University of Medical Sciences

askariv@mums.ac.ir+98 51 3800 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026